 Your new post is loading...
 Your new post is loading...
|
Scooped by
Gilbert C FAURE
November 21, 2023 5:22 AM
|
Hematologic malignancies (blood cancers) are diseases of immune system cells and are traditionally categorized according to where the cancer is first detected.
|
Scooped by
Gilbert C FAURE
October 5, 2023 2:43 AM
|
The amount of data collected with cytometers keeps increasing. With studies measuring up to 40 markers, millions of cells per sample and up to thousands of samples, manual gating of all this data becomes infeasible. In this summer school, we will have workshops on all steps of a computational cytometry pipeline in R. On Monday morning, we offer two tracks, one for people with a cytometry background and one for people with a computational background. From Monday afternoon onwards, we will dive into the computational cytometry specifics. We will cover data cleaning, cell population identification and downstream statistics. In addition, we will also have some sessions where these concepts are demonstrated on commercial platforms, such as FlowJo, FCSExpress and OMIQ.
|
Scooped by
Gilbert C FAURE
September 24, 2023 4:00 AM
|
IntroductionThe three groups of helper innate lymphoid cells (ILCs), namely ILC1, ILC2 and ILC3, have been identified by flow cytometry by combinations of cell surface markers. Here, we review various ways ILCs are currently identified, focusing on potential problems and their solutions. The first step to identify all ILCs is to exclude other lymphocytes and myeloid cells by their lineage-specific markers (Lin). However, the Lin cocktail varies in various studies, and the definition of Lin- population containing ILCs is often ambiguous, resulting in contamination of Lin+ cells, particularly T cells.MethodWe have designed combinations of cell surface markers to identify ILC populations in various tissues of B6 mice by flow cytometry. To minimize T cell contamination, TCR/CD3ϵ antibodies were used separately from the Lin cocktail. ILCs identified by surface markers are confirmed by the expression of the transcription factors GATA3, RORγt, T-bet and Eomes.ResultILC1s in the B6 mouse liver are identified by Lin-NKp46+NK1.1+TCR/CD3ϵ−CD49a+CD49b−. However, defining ILC1s in other tissues remains a challenge. ILC2s in the lung are identified by Lin−TCR/CD3ϵ− Thy1+CD127+ST2+ whereas ILC2s in the small intestine and liver are identified by Lin−TCR/CD3ϵ−Thy1+GATA3+RORγt−. ILC3s in B6 mouse spleen, liver, lung and small intestine are identified by Lin−TCR/CD3ϵ− Thy1+CD127+RORγt+.DiscussionThe ILC population is heterogeneous and the strategies to identify ILCs have to be designed fo
|
Scooped by
Gilbert C FAURE
September 5, 2023 2:39 AM
|
CRUSTY is a web-tool for clustering analysis designed for high-dimensional single-cell data.
|
Scooped by
Gilbert C FAURE
July 28, 2023 2:50 AM
|
🩸 Delighted to share this article on the characterization of viable CTCs with you ! Good reading !!!! 💫 #liquidbiopsy #circulatingtumorcells #CTCs #cancer…
|
Scooped by
Gilbert C FAURE
July 1, 2023 4:15 AM
|
Your cytometry learning portal.
|
Scooped by
Gilbert C FAURE
June 24, 2023 4:48 AM
|
Probiotic enumeration is a key testing component to ensure reliable and compliant products reach consumers. Eurofins offers a unique ISO 17025 accredited flow cytometry method for probiotic enumeration. Flow cytometry offers faster turn-around times and reduced relative standard deviation compared to traditional plating methods. However, limitations also exist for flow cytometry applications.
|
Scooped by
Gilbert C FAURE
May 13, 2023 4:57 AM
|
Although immunotherapy is becoming a standard approach of human cancer treatment, only a small but critical fraction of patients responds to the therapy. It is therefore required to determine the sub-populations of patients who will respond to immunotherapies along with developing novel strategies...
|
Scooped by
Gilbert C FAURE
April 11, 2023 4:34 AM
|
Over the last decade, liquid biopsy has gained much attention as a powerful tool in personalized medicine since it enables monitoring cancer evolution and follow-up of cancer patients in real time. Through minimally invasive procedures, liquid biopsy provides important information through the analysis of circulating tumour cells (CTCs) and circulating tumour-derived material, such as circulating tumour DNA (ctDNA), circulating miRNAs (cfmiRNAs) and extracellular vehicles (EVs). CTC analysis has already had an important impact on the prognosis, detection of minimal residual disease (MRD), treatment selection and monitoring of cancer patients. Numerous clinical trials nowadays include a liquid biopsy arm. CTC analysis is now an exponentially expanding field in almost all types of solid cancers. Functional studies, mainly based on CTC-derived cell-lines and CTC-derived explants (CDx), provide important insights into the metastatic process. The purpose of this review is to summarize the latest findings on the clinical significance of CTCs for the management of cancer patients, covering the last four years. This review focuses on providing a comprehensive overview of CTC analysis in breast, prostate and non-small-cell lung cancer. The unique potential of CTC single-cell analysis for understanding metastasis biology, and the importance of quality control and standardization of methodologies used in this field, is also discussed.
|
Scooped by
Gilbert C FAURE
March 3, 2023 4:24 AM
|
Neutrophils are a vital component of the innate immune system and play an essential function in the recognition and clearance of bacterial and fungal pathogens. There is great interest in understanding mechanisms of neutrophil dysfunction in the setting of disease and deciphering potential side...
|
Scooped by
Gilbert C FAURE
February 28, 2023 4:47 AM
|
This Flow Cytometry Course is aimed at both clinical applications and applications in cell biology and is open to all and is suitable for those who are relatively new to flow cytometry and who wish to expand their experience with applications and specific analysis.
|
Scooped by
Gilbert C FAURE
February 3, 2023 2:45 AM
|
Extracellular vesicles can provide a wealth of information, but these intriguing messengers are notoriously difficult to detect. This could be about to change.
|
Scooped by
Gilbert C FAURE
December 20, 2022 11:38 AM
|
Cancer-related deaths are mainly caused by metastatic spread of tumor cells from the primary lesion to distant sites via the blood circulation. Understanding the mechanisms of blood-borne tumor cell dissemination by the detection and molecular characterization of circulating tumor cells (CTCs) in th …
|
|
Scooped by
Gilbert C FAURE
November 14, 2023 5:46 AM
|
The limited sensitivity of circulating tumor cell (CTC) detection in pancreatic adenocarcinoma (PDAC) stems from their extremely low concentration in the whole circulating blood, necessitating enhanced detection methodologies. This study sought to amplify assay-sensitivity by employing diagnostic leukapheresis (DLA) to screen large blood volumes. Sixty patients were subjected to DLA, with a median processed blood volume of ~ 2.8 L and approximately 5% of the resulting DLA-product analyzed using CellSearch (CS). Notably, DLA significantly increased CS-CTC detection to 44% in M0-patients and 74% in M1-patients, yielding a 60-fold increase in CS-CTC enumeration. DLA also provided sufficient CS-CTCs for genomic profiling, thereby delivering additional genomic information compared to tissue biopsy samples. DLA CS-CTCs exhibited a pronounced negative prognostic impact on overall survival (OS), evidenced by a reduction in OS from 28.6 to 8.5 months (univariate: p = 0.002; multivariable: p = 0.043). Additionally, a marked enhancement in sensitivity was achieved (by around 3-4-times) compared to peripheral blood (PB) samples, with positive predictive values for OS being preserved at around 90%. Prognostic relevance of CS-CTCs in PDAC was further validated in PB-samples from 228 PDAC patients, consolidating the established association between CTC-presence and reduced OS (8.5 vs. 19.0 months, p < 0.001). In conclusion, DLA-derived CS-CTCs may serve as a viable tool for identifying high-risk PDAC-patients and aiding the optimization of multimodal treatment strategies. Moreover, DLA enables comprehensive diagnostic profiling by providing ample CTC material, reinforcing its utility as a reliable liquid-biopsy approach. This high-volume liquid-biopsy strategy presents a potential pathway for enhancing clinical management in this malignancy.
|
Scooped by
Gilbert C FAURE
October 3, 2023 8:28 AM
|
World Experts. Your Colleagues. Join Us. You are cordially invited to attend ICCS 2023, the 38th Annual International Clinical Cytometry Meeting & Course. Please join your clinical cytometry colleagues from September 29 - October 3, 2023.
|
Scooped by
Gilbert C FAURE
September 21, 2023 1:33 PM
|
Cells, an international, peer-reviewed Open Access journal.
|
Scooped by
Gilbert C FAURE
August 17, 2023 2:29 AM
|
📢 What to know how cancer cells change their identity to evolve and escape therapy? Check out our latest review in Cancer Discovery that presents unifying…
|
Scooped by
Gilbert C FAURE
July 2, 2023 3:57 AM
|
Check the newest paper from Cíntia Marques, Olivier Jordan, Gerrit Borchard (he/him) from Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO)-…
|
Scooped by
Gilbert C FAURE
June 25, 2023 2:26 PM
|
Tumorrestzellen: Standardisierte Flüssigbiopsien sollen Krebstherapie verbessern
|
Scooped by
Gilbert C FAURE
June 16, 2023 8:23 AM
|
According to the new market research report "Flow Cytometry Market Size, Growth by Technology (Cell-based, Bead-based), Product & Service (Analyzer, Sorter, Consumables, Software), Application ((Research - Immunology, Stem cell), (Clinical - Hematology)), End user (Biotech, Hospitals) - Global Forec...
|
Scooped by
Gilbert C FAURE
April 19, 2023 2:46 AM
|
A conversation with Gert Van Isterdael, Head of VIB Flow Core at the VIB-UGent Center for Inflammation Research
|
Scooped by
Gilbert C FAURE
March 3, 2023 4:26 AM
|
Background and Objective. Reference ranges are necessary in clinical chemistry and hematology to compare an observed value and to provide meaningfu...
|
Scooped by
Gilbert C FAURE
February 28, 2023 4:48 AM
|
Researchers from the University of Technology Sydney have developed a new device that can detect and analyze cancer cells from blood samples, enabling doctors to avoid invasive biopsy surgeries, and to monitor treatment progress.
|
Scooped by
Gilbert C FAURE
February 28, 2023 4:45 AM
|
In this webinar, Mirko Corselli discusses the similarities, differences, and advantages of spectral flow cytometry compared to conventional flow.
|
Scooped by
Gilbert C FAURE
December 26, 2022 7:25 AM
|
The potential clinical utility of circulating tumor cells (CTCs) in the diagnosis and management of cancer has drawn a lot of attention in the past 10 years. CTCs disseminate from tumors into the bloodstream and are believed to carry vital information about tumor onset, progression, and metastasis. In addition, CTCs reflect different biological aspects of the primary tumor they originate from, mainly in their genetic and protein expression. Moreover, emerging evidence indicates that CTC liquid biopsies can be extended beyond prognostication to pharmacodynamic and predictive biomarkers in cancer patient management. A key challenge in harnessing the clinical potential and utility of CTCs is enumerating and isolating these rare heterogeneous cells from a blood sample while allowing downstream CTC analysis. That being said, there have been serious doubts regarding the potential value of CTCs as clinical biomarkers for cancer due to the low number of promising outcomes in the published results. This review aims to present an overview of the current preclinical CTC detection technologies and the advantages and limitations of each sensing platform, while surveying and analyzing the published evidence of the clinical utility of CTCs.
|